Latest Conference Coverage

Phase 3 data show tenecteplase before thrombectomy in late basilar artery stroke adds no functional benefit, with similar bleeding and mortality.

The professor of neurology at the University of Alabama at Birmingham talked about findings from a CREST-2 substudy presented at ISC 2026 showing that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. [WATCH TIME: 5 minutes]

A duo of experts at ISC 2026 discussed results from a clinical trial of high-dose, home-based constraint-induced movement therapy in infants with perinatal arterial ischemic stroke. [WATCH TIME: 5 minutes]

The Allen Geller distinguished professor of immunology at Duke University School of Medicine discusses the connection between Epstein Barr Virus and Multiple Sclerosis, citing decades of research that position EBV as a leading environmental risk factor and a potential therapeutic target in MS. [WATCH TIME: 4 minutes]

Phase 2 MoonStone trial shows obexelimab sharply cuts new MRI lesions in relapsing MS by week 12, with convenient, weekly self-injection.

In the phase 3 PERSEUS trial, BTK inhibitor tolebrutinib did not significantly reduce disability progression compared with placebo in patients with primary progressive multiple sclerosis.

The assistant professor of medicine at the University of Toronto discussed whether multiple sclerosis can develop prior to Epstein–Barr virus infection and what new population data reveal about the long-standing causality debate. [WATCH TIME: 4 minutes]

New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis provided background on a study presented at ACTRIMS 2026 focused on patient-reported barriers to timely multiple sclerosis treatment initiation. [WATCH TIME: 4 minutes]

Phase 3 DAWN data show daratumumab cuts NMOSD relapse risk 76%, stays well tolerated, and may improve disability, signaling a new targeted option.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

The associate professor of neurology at the University of California, San Francisco discussed the evolving approach to remyelination in patients with MS at the 2026 ACTRIMS Forum. [WATCH TIME: 3 minutes]

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

The professor of neurology at Cleveland Clinic discussed how evolving imaging and biological insights have reshaped the way clinicians define and talk about multiple sclerosis. [WATCH TIME: 3 minutes]

Ultragenyx seeks FDA accelerated approval for UX111 gene therapy in Sanfilippo syndrome, citing neurologic benefit and the use of cerebral spinal fluid heparan sulfate data.

The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

The senior research investigator at the New York Stem Cell Foundation discussed how human iPSC-based models can help dissect the cellular mechanisms underlying PIRA and progressive disability in multiple sclerosis. [WATCH TIME: 3 minutes]

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.